SpringerLink
Log in

Parkinsonmittel

  • Chapter
Arzneiverordnungs-Report 2005

  • 466 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

eBook
EUR 26.99
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arnold G, Kupsch A (2000): Hemmung der Catechol-O-Methyltransferase. Optimierung der dopaminergen Therapie beim idiopathischen Parkinsonsyndrom mit Entacapone. Nervenarzt 71: 78–83.

    Article  CAS  PubMed  Google Scholar 

  • Clarke CE (2004): A „cure“ for Parkinson’s disease: can neuroprotection be proven with current trial designs? Mov Disord 19:491–498.

    Article  PubMed  Google Scholar 

  • Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;(1):CD003468.

    Google Scholar 

  • Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004554.

    Google Scholar 

  • Deutsche Gesellschaft für Neurologie (2003): Leitlinie Parkinson-Syndrome. www.dgn.org/168.0.html.

    Google Scholar 

  • Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999): Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908–1910.

    CAS  PubMed  Google Scholar 

  • Hattori N, Mizuno Y (2004): Pathogenetic mechanisms of parkin in Parkinson’s disease. Lancet 364: 722–724.

    Article  CAS  PubMed  Google Scholar 

  • Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;(2):CD003735.

    Google Scholar 

  • Koller WC, Tse W (2004): Unmet medical needs in Parkinson’s disease. Neurology 62(Suppl 1): S1–8.

    CAS  PubMed  Google Scholar 

  • Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 311: 1602–1607.

    CAS  PubMed  Google Scholar 

  • Mejer Nielsen B (1983): Tiapride in levodopa-induced involuntary movements. Acta Neurol Scand 67: 372–375.

    CAS  PubMed  Google Scholar 

  • Parkinson Study Group (2000): Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284: 1931–1938.

    Article  Google Scholar 

  • Parkinson Study Group (2002): Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653–1661.

    Article  Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484–1491.

    Article  CAS  PubMed  Google Scholar 

  • Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158.

    CAS  PubMed  Google Scholar 

  • Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003): 3,4-methylenedioxymethamphetamine (MDMA, „Ecstasy“) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223–1229.

    Article  CAS  PubMed  Google Scholar 

  • Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group (2002): Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541–1550.

    Article  PubMed  Google Scholar 

  • Siderowf A, Stern M (2003): Update on Parkinson disease. Ann Intern Med 138: 651–658.

    PubMed  Google Scholar 

  • Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson’s disease. Neurology 50(Suppl 6): S18–S22; discussion S44-S48.

    CAS  PubMed  Google Scholar 

  • The Parkinson Study Group (1993): Effects of tocopherol and deprenyl on the progression of disability in early parkinson’s disease. N Engl J Med 328: 176–183.

    Article  Google Scholar 

  • Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004): Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363: 1179–1183.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2006). Parkinsonmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2005. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30505-X_42

Download citation

  • DOI: https://doi.org/10.1007/3-540-30505-X_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28368-3

  • Online ISBN: 978-3-540-30505-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation